Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study - Archive ouverte HAL Access content directly
Journal Articles Alimentary Pharmacology & Therapeutics (Suppl) Year : 2019

Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study

(1) , (2) , (3) , (4) , (5) , (6) , (7) , (8) , (9) , (10) , (11) , (12) , (13) , (14) , (15) , (16) , (17, 18, 19, 20) , (21) , (22) , (23) , (24) , (25) , (26) , (27) , (28) , (29)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
Xavier Roblin
  • Function : Author
  • PersonId : 886939
Romain Altwegg
  • Function : Author
Philippe Marteau
  • Function : Author
  • PersonId : 914789
Matthieu Allez
Not file

Dates and versions

hal-02362791 , version 1 (14-11-2019)

Identifiers

Cite

Aurélien Amiot, Mélanie Serrero, Laurent Peyrin-Biroulet, Jérome Filippi, Benjamin Pariente, et al.. Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study. Alimentary Pharmacology & Therapeutics (Suppl), 2019, 50 (1), pp.40-53. ⟨10.1111/apt.15294⟩. ⟨hal-02362791⟩
77 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More